Global Remdesivir (COVID 19) Market Size, Share, Forecast Report, 2020-2027

Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 41 in /home/multiwpmr/public_html/report-details.php on line 448

Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 44 in /home/multiwpmr/public_html/report-details.php on line 448
The global Remdesivir (COVID 19) market garnered revenue around USD XX Billion in 2019 and projected to reach USD 10 Billion in 2027, with at a compound annual growth rate of 31.6% throughout the estimate period from 2020 to 2027.

Remdesivir is an antiviral medication developed by biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. In March 2020 a research performed by Gilead Sciences Inc. on 53 prospective COVID-19 patients showed signs of progress in 36 patients, about 68% of the total number of patients.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Remdesivir (COVID 19) market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Remdesivir (COVID 19) market growth.

The global Remdesivir (COVID 19) market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Gilead Sciences, Inc. (US)

Mylan (US)

Cipla (India)

Hetero Labs (India)

Jubilant Life Sciences (India)

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Dosage

The Remdesivir drug is being used as an emergency drug for the treatment of COVID 19. Different doses are being given to the patients according to the age groups and weight but mainly 100 mg dosage dominating the remdesivir market globally.

� 5mg: for pediatric patients weighing 3.5 kg to less than 40 kg, use remdesivir for injection, 100 mg, and lyophilized powder only.

� 10 mg: 10 mg dosage was firstly used on rhesus monkeys before human beings using IV bolus injection initiated 12 hours post-inoculation with SARS-CoV-2 resulted in a reduction in clinical signs of respiratory disease, lung pathology, and gross lung lesions, and lung viral RNA levels compared with vehicle-treated animals.

� 100mg: The recommended dosage of remdesivir for pediatric patients weighing 40 kg and higher is the adult dosage regimen of a single loading dose of 200 mg on Day 1 followed by once-daily maintenance doses of 100 mg from Day 2.

By Distribution Channel

� Hospitals: While distribution is being handled by a commercial drug distributor, decisions regarding which hospitals get the drug have been left to government authorities. The drug is an infusion and will not be given to retail and specialty pharmacies. The distribution of remdesivir has been authorized only for the treatment of hospitalized patients with severe COVID-19. It is not authorized for the treatment of any other viruses or pathogens.

� Drug stores: The government has not permitted drug stores to sell the remdesivir drug in the market. The drug is only being given in hospitals directly from manufacturers. Depending upon the success rate and side effects the drug can be approved in the drug store for the sale.



Regional Analysis and Forecast



Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:



� North America

? U.S.

? Canada

� Europe

? Germany

? U.K.

? Italy

? France

? Rest of EU

� Asia Pacific

? China

? India

? Japan

? Southeast Asia

? Rest of APAC

� Central & South America

? Brazil

? Argentina

? Rest of Central & South America

� Middle East and Africa

? UAE

? Saudi Arabia

? Rest of MEA